Sarepta Therapeutics Inc (SRPT)
127.36
+3.11
(+2.50%)
USD |
NASDAQ |
Apr 25, 16:00
127.36
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Cash from Financing (TTM): 125.00M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 125.00M |
September 30, 2023 | 133.81M |
June 30, 2023 | 334.83M |
March 31, 2023 | 329.31M |
December 31, 2022 | 232.51M |
September 30, 2022 | 771.01M |
June 30, 2022 | 560.48M |
March 31, 2022 | 563.67M |
December 31, 2021 | 561.57M |
September 30, 2021 | 339.26M |
June 30, 2021 | 352.14M |
March 31, 2021 | 366.19M |
December 31, 2020 | 682.32M |
September 30, 2020 | 612.35M |
June 30, 2020 | 595.30M |
March 31, 2020 | 584.01M |
December 31, 2019 | 642.55M |
September 30, 2019 | 906.87M |
June 30, 2019 | 881.18M |
March 31, 2019 | 900.24M |
December 31, 2018 | 530.15M |
September 30, 2018 | 515.68M |
June 30, 2018 | 921.87M |
March 31, 2018 | 895.35M |
December 31, 2017 | 888.08M |
Date | Value |
---|---|
September 30, 2017 | 388.56M |
June 30, 2017 | 340.03M |
March 31, 2017 | 379.37M |
December 31, 2016 | 378.13M |
September 30, 2016 | 496.42M |
June 30, 2016 | 164.28M |
March 31, 2016 | 146.36M |
December 31, 2015 | 147.81M |
September 30, 2015 | 22.26M |
June 30, 2015 | 26.09M |
March 31, 2015 | 101.87M |
December 31, 2014 | 104.16M |
September 30, 2014 | 106.10M |
June 30, 2014 | 239.70M |
March 31, 2014 | 145.39M |
December 31, 2013 | 145.67M |
September 30, 2013 | 300.96M |
June 30, 2013 | 183.33M |
March 31, 2013 | 181.59M |
December 31, 2012 | 178.60M |
September 30, 2012 | 21.32M |
June 30, 2012 | -0.05M |
March 31, 2012 | 32.18M |
December 31, 2011 | 32.30M |
September 30, 2011 | 32.34M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
125.00M
Minimum
Dec 2023
906.87M
Maximum
Sep 2019
503.91M
Average
561.57M
Median
Dec 2021
Cash from Financing (TTM) Benchmarks
PTC Therapeutics Inc | 646.40M |
Vertex Pharmaceuticals Inc | -562.20M |
Regenxbio Inc | -34.97M |
CytomX Therapeutics Inc | 30.23M |
Apellis Pharmaceuticals Inc | 394.50M |